Bicara Therapeutics (BCAX) Retained Earnings (2023 - 2026)

Bicara Therapeutics has reported Retained Earnings for 4 years, with the latest figure at -$415.2 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 60.99% year-over-year to -$415.2 million; the trailing twelve-month figure through Mar 2026 stood at -$415.2 million (down 60.99% YoY), and the FY2025 full-year result was $243000.0, up 100.11% from the prior year.
• Retained Earnings for Q1 2026 stood at -$415.2 million, down from $243000.0 in the prior quarter.
• The five-year high for Retained Earnings was $243000.0 in Q4 2025, with the low at -$415.2 million in Q1 2026.
• Historically, Retained Earnings has averaged -$231.7 million across 4 years, with a median of -$239.5 million in 2024.
• Annual changes were most pronounced in 2025 — Retained Earnings surged 100.11% — and 2026, when it slumped 60.99%.
• Bicara Therapeutics' Retained Earnings stood at -$153.0 million in 2023, then plunged by 44.44% to -$221.0 million in 2024, then surged by 100.11% to $243000.0 in 2025, then slumped by 170964.2% to -$415.2 million in 2026.
• The last three Retained Earnings figures came in at -$415.2 million (Q1 2026), $243000.0 (Q4 2025), and -$321.6 million (Q3 2025), per Business Quant data.